Skip to main content
OpenTrials
Completed

NCT Number: NCT03969537

Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections

Many cervical dystonia (CD) patients are limited in their ability to travel to the clinic for follow-up in between injection visits.

A telemedicine visit at the time of peak effectiveness of neurotoxin treatment may be valuable in informing the neurologist's choice of muscle selection and/or dose for the next injection visit. The primary objective of this study is to investigate both patient and physician satisfaction with the use of our telemedicine tool for this type of follow-up. After assessment of the subject, the neurologist will decide whether or not the telemedicine visit was informative to the upcoming injection visit. Subjects will answer questions at the end of the visit regarding their satisfaction with the follow-up and overall telemedicine communication. The principle investigator will complete a similar survey with additional questions about information gathered from the visit to assess the primary objective.

A secure video communications platform will be used for the visit, which will occur 2-4 weeks after the patient's last neurotoxin injection (around the time of peak effectiveness). The investigating neurologist will remotely assess the patient and make notes for the next injection visit.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects of any race, aged 18 and above
  • Diagnosed with cervical dystonia and being treated with neurotoxin injections at Vanderbilt University Medical Center
  • The subject, or if appropriate their medical decision maker, is willing and able to provide written informed consent.
  • Email and internet access
  • Personal computing device with audio/video capability

Exclusion criteria

  • Subjects for whom participation in the study may cause medical harm

Treatment and study plan

Telemedicine follow-up visit

Other

Study participants will experience two telemedicine (live audio/video) visits.

Primary outcomes

  1. Patient Satisfaction with Telehealth

    Time frame: 4 months

    This questionnaire measures patient satisfaction with the telehealth visit scored 7 to 27

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Collaborators

  • The Allergan Foundation

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
May 31, 2019
Registry last updated
Nov 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.